Stratifying drug treatment of cognitive impairments after traumatic brain injury using neuroimaging.

Peter O Jenkins¹, Sara De Simoni¹, Niall J Bourke¹, Jessica Fleminger¹, Gregory Scott¹, David J Towey², William Svensson², Sameer Khan², Maneesh C Patel³, Richard Greenwood⁴, Daniel Friedland¹, Adam Hampshire¹, James H Cole¹, David J Sharp^1,5

¹Computational, Cognitive and Clinical Neuroimaging Laboratory, Imperial College London, Division of Brain Sciences, Hammersmith Hospital, London, UK.

²Department of Nuclear Medicine, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK.

³Imaging Department, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK.

⁴Institute of Neurology, Division of Clinical Neurology, University College London, London, UK.

⁵United Kingdom (UK) Dementia Research Institute, 6th Floor, UCL Maple House Tottenham Court Road, London, W1T 7NF, UK.

PubMed DOI

Abstract

Cognitive impairment is common following traumatic brain injury. Dopaminergic drugs can enhance cognition after traumatic brain injury, but individual responses are highly variable. This may be due to variability in dopaminergic damage between patients. We investigate whether measuring dopamine transporter levels using 123I-ioflupane single-photon emission computed tomography (SPECT) predicts resp…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.